Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for
What does CAR-T safety look like between autoimmune disease and heme-onc? Here's CRS and ICANS within the cohorts so far (although don't forget about the lymphodepletion) Anca Askanase @HSpecialSurgery #ACR26 @RheumNow https://t.co/GkDGDiOET4
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
CD19 CAR-T relapse: 8/55 (14.5%), median 16.5 mo SLE 6.5%, SSc 20% (Scl70+), IIM 37.5% (ASyS) Relapsers: B-cell aplasia 77 vs 148 d, autoAb ↓26% vs ↓100% at M12 BCMA rescue: 7/7 major responses A flat autoAb curve is the warning sign. Abstr#2632 @RheumNow #ACR26 https://t.co/VFUiUN0FMG
Can CAR-T create new autoimmune disease? First observed in rheumatology by @DrGomezPuerta, now @MayoClinic similar estimates - this time 1.3% far less phenotypically clear than ICI causality hard to put together but definitely worth us watching ABST0744 #ACR26 @RheumNow https://t.co/iQbJBNCeWT
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
